Affordable Access

Access to the full text

COVID-19: Living through Another Pandemic

  • Osman, Essam Eldin A.1, 2
  • Toogood, Peter L.1, 1
  • Neamati, Nouri1
  • 1 University of Michigan, United States , (United States)
  • 2 Cairo University, Egypt , (Egypt)
Published Article
ACS Infectious Diseases
American Chemical Society
Publication Date
May 10, 2020
DOI: 10.1021/acsinfecdis.0c00224
PMID: 32388976
PMCID: PMC7216760
PubMed Central


Novel beta-coronavirus SARS-CoV-2 is the pathogenic agent responsible for coronavirus disease-2019 (COVID-19), a globally pandemic infectious disease. Due to its high virulence and the absence of immunity among the general population, SARS-CoV-2 has quickly spread to all countries. This pandemic highlights the urgent unmet need to expand and focus our research tools on what are considered “neglected infectious diseases” and to prepare for future inevitable pandemics. This global emergency has generated unprecedented momentum and scientific efforts around the globe unifying scientists from academia, government and the pharmaceutical industry to accelerate the discovery of vaccines and treatments. Herein, we shed light on the virus structure and life cycle and the potential therapeutic targets in SARS-CoV-2 and briefly refer to both active and passive immunization modalities, drug repurposing focused on speed to market, and novel agents against specific viral targets as therapeutic interventions for COVID-19.

Report this publication


Seen <100 times